NASDAQ:ANIK Anika Therapeutics (ANIK) Stock Price, News & Analysis $14.82 -0.21 (-1.36%) As of 12:50 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Anika Therapeutics Stock (NASDAQ:ANIK) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Anika Therapeutics alerts:Sign Up Key Stats Today's Range$14.80▼$15.0750-Day Range$12.39▼$16.0052-Week Range$7.87▼$16.24Volume14,614 shsAverage Volume133,678 shsMarket Capitalization$197.13 millionP/E RatioN/ADividend YieldN/APrice Target$17.00Consensus RatingHold Company Overview Anika Therapeutics, Inc. is a life sciences company specializing in the development and commercialization of hyaluronic acid–based therapeutic products. The company focuses on orthobiologics and medical devices designed to support joint health, tissue repair and surgical applications. Anika’s proprietary hyaluronan technology serves as the foundation for products aimed at alleviating pain associated with osteoarthritis and enhancing healing in musculoskeletal and ophthalmic surgeries. The company’s core product portfolio includes injectable viscosupplements such as Monovisc® and Orthovisc®, which are indicated for the relief of knee osteoarthritis pain, as well as Euflexxa®, approved for osteoarthritis of the knee in various international markets. Beyond viscosupplementation, Anika has expanded into adjacent areas with products for wound repair, surgical adhesion prevention and dermatological applications, leveraging its hyaluronan platform to address diverse clinical needs. Founded in 1992 and headquartered in Bedford, Massachusetts, Anika maintains a global presence through direct subsidiaries and a network of distributors across North America, Europe and Asia Pacific. Since its public offering, the company has invested in manufacturing scale-up and research collaborations to drive innovation in biomaterials and extend its market reach into new therapeutic segments. Leadership at Anika is headed by President and Chief Executive Officer Nam Rhee, under whose tenure the company has pursued strategic partnerships, product lifecycle extensions and pipeline development. Anika’s management team combines expertise in biotechnology, regulatory affairs and commercial operations to support ongoing growth and shareholder value creation.AI Generated. May Contain Errors. Read More Anika Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreANIK MarketRank™: Anika Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 604th out of 858 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.3 / 5Analyst RatingHold Consensus RatingAnika Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialAnika Therapeutics has a consensus price target of $17.00, representing about 13.2% upside from its current price of $15.02.Amount of Analyst CoverageAnika Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Anika Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Anika Therapeutics are expected to grow in the coming year, from ($0.74) to ($0.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Anika Therapeutics is -19.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anika Therapeutics is -19.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnika Therapeutics has a P/B Ratio of 1.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Anika Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.72% of the float of Anika Therapeutics has been sold short.Short Interest Ratio / Days to CoverAnika Therapeutics has a short interest ratio ("days to cover") of 4.28.Change versus previous monthShort interest in Anika Therapeutics has recently decreased by 14.32%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAnika Therapeutics does not currently pay a dividend.Dividend GrowthAnika Therapeutics does not have a long track record of dividend growth. News and Social Media2.4 / 5News Sentiment0.84 News SentimentAnika Therapeutics has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Anika Therapeutics this week, compared to 3 articles on an average week. Company Ownership4.7 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of Anika Therapeutics in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $223,238.00 in company stock, which represents 0.1117% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Anika Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $223,238.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders12.08% of the stock of Anika Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions91.53% of the stock of Anika Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Anika Therapeutics' insider trading history. Receive ANIK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anika Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ANIK Stock News HeadlinesAnika Therapeutics (NASDAQ:ANIK) Stock Crosses Above Two Hundred Day Moving Average - What's Next?May 16, 2026 | americanbankingnews.comInsider Buying: Anika Therapeutics (NASDAQ:ANIK) Director Buys 5,000 Shares of StockMay 5, 2026 | insidertrades.comHow to Profit from Elon’s AI lab before it goes publicElon Musk's AI lab has partnered with the Department of Defense, Oracle, and Palantir - and he just filed confidential IPO paperwork. By the time it goes public, most investors will have missed the biggest gains. Louis Navellier, a 47-year Wall Street veteran who has recommended over 675 stocks that climbed 100% or more, says he's found a way to profit ahead of the IPO. He's backed his conviction with $358 million of his own firm's money. Goldman Sachs projects the underlying technology could surge 70X over the next decade.May 22 at 1:00 AM | InvestorPlace (Ad)President of Anika Therapeutics Picks Up 51% More StockMay 3, 2026 | finance.yahoo.comAnika Therapeutics (NASDAQ:ANIK) CEO Stephen Griffin Purchases 12,200 SharesMay 1, 2026 | insidertrades.comBullish On Anika Therapeutics's Pullback As Integrity ScalesApril 30, 2026 | seekingalpha.comAnika Therapeutics Signals Momentum Amid Regulatory HurdlesApril 29, 2026 | tipranks.comAnika Therapeutics Inc.: Anika Reports First Quarter 2026 Financial ResultsApril 29, 2026 | finanznachrichten.deSee More Headlines ANIK Stock Analysis - Frequently Asked Questions How have ANIK shares performed this year? Anika Therapeutics' stock was trading at $9.61 at the beginning of the year. Since then, ANIK shares have increased by 56.3% and is now trading at $15.02. How were Anika Therapeutics' earnings last quarter? Anika Therapeutics Inc. (NASDAQ:ANIK) issued its earnings results on Wednesday, April, 29th. The biotechnology company reported $0.27 EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.34. The biotechnology company earned $29.61 million during the quarter, compared to the consensus estimate of $28.14 million. Anika Therapeutics had a negative net margin of 9.52% and a negative trailing twelve-month return on equity of 5.90%. Read the conference call transcript. Who are Anika Therapeutics' major shareholders? Top institutional shareholders of Anika Therapeutics include Renaissance Technologies LLC (3.77%), Dimensional Fund Advisors LP (3.45%), Quantinno Capital Management LP (0.95%) and Hsbc Holdings PLC (0.38%). Insiders that own company stock include John B Henneman III and Stephen D Griffin. View institutional ownership trends. How do I buy shares of Anika Therapeutics? Shares of ANIK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Anika Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Anika Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Advanced Micro Devices (AMD), ServiceNow (NOW) and Arista Networks (ANET). Company Calendar Last Earnings4/29/2026Today5/22/2026Next Earnings (Estimated)7/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 3 weeks, ANIK's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryHealth Care Supplies Current SymbolNASDAQ:ANIK CIK898437 Webwww.anikatherapeutics.com Phone(781) 457-9000Fax781-305-9720Employees300Year Founded1992Price Target and Rating Average Price Target for Anika Therapeutics$17.00 High Price Target$17.00 Low Price Target$17.00 Potential Upside/Downside+14.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$10.88 million Net Margins-9.52% Pretax Margin-8.82% Return on Equity-5.90% Return on Assets-4.52% Debt Debt-to-Equity RatioN/A Current Ratio4.46 Quick Ratio3.37 Sales & Book Value Annual Sales$116.26 million Price / Sales1.70 Cash FlowN/A Price / Cash FlowN/A Book Value$10.06 per share Price / Book1.47Miscellaneous Outstanding Shares13,306,000Free Float11,699,000Market Cap$197.13 million OptionableOptionable Beta0.16 Social Links Beginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:ANIK) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersHow to Profit from Elon’s AI lab before it goes publicElon Musk's AI lab has partnered with the Department of Defense, Oracle, and Palantir - and he just filed conf...InvestorPlace | SponsoredMaybe the Greatest Strategy of the DecadeNate Bear, Lead Technical Tactician at Monument Traders Alliance, is going public with his highest-conviction ...Monument Traders Alliance | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredOne filing just changed the SpaceX IPO foreverSpaceX just filed its S-1. The IPO is confirmed for June 12 - $75 billion, ticker SPCX, potentially the larges...Behind the Markets | SponsoredSpaceX controls two-thirds of all satellites - and it is about to go publicSpaceX is targeting an IPO on June 11th, with trading set to begin June 12th and the roadshow kicking off June...NXT Wave Research | SponsoredTo Avoid 67 Million Blackouts, Trump Signs Emergency Backing of New Energy TechPresident Trump has used emergency executive powers to back a new energy technology described as 326 times mor...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anika Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anika Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
